Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Caroline Lohrisch"'
Autor:
Jorge Riera-Knorrenschild, Mounir Aout, Jose Perez-Garcia, Rosanne Serpanchy, Jozef Šufliarský, Christine Wohlfarth, Peter C. Thuss-Patience, Javier Cortes, Michelino De Laurentiis, Sylvie Lorenzen, Dina Sakaeva, Filippo Montemurro, Giacomo Allegrini, Véronique Diéras, Natsumi Irahara, Francesco Ricci, Caroline Lohrisch, Maria Vidal, Karen A. Gelmon, Eva Oravcová
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
JAMA Oncol
Universidad de Barcelona
JAMA Oncol
IMPORTANCE: ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy and quality of life. OBJECTIVE: To determine maximum tolerated doses (MTDs) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51bece98e9fb3e26d2f0f7a1460184b7
http://hdl.handle.net/2445/176631
http://hdl.handle.net/2445/176631
Autor:
M. Mates, Penelope A. Bradbury, Caroline Lohrisch, Rachel Anne Goodwin, Ming-Sound Tsao, Stephen Chia, Shingo Sakashita, Tao Wang, Karen A. Gelmon, Susan Ellard, Catalin Mihalcioiu, Sara Kristina Taylor, Stephen Welch, Vikaash Kumar, Elizabeth A. Eisenhauer, Wilson H. Miller, Linda Hagerman
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-8 (2017)
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Background The mechanisms of resistance to anti-human epidermal growth factor receptor 2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met), vascular endothelial growth factor (VEGF) and AXL pathways. Foretinib is a
Autor:
Caroline Lohrisch, Stephen Chia, Laurel Kovacic, Suzanne C. Malfair Taylor, Caroline Speers, Lindsay Hedden, Stuart Peacock, Susan E. O'Reilly
Publikováno v:
The Oncologist. 17:164-171
Background. Among women with surgically removed, high-risk HER-2/neu-positive breast cancer, trastuzumab has demonstrated significant improvements in disease-free and overall survival. The objective of this study is to evaluate the cost-effectiveness
Autor:
Martine Piccart, Caroline Lohrisch
Publikováno v:
Seminars in Oncology. 28:3-11
HER2 is a transmembrane growth factor receptor found in normal and malignant breast epithelial cells. Phosphorylation of the intracellular tyrosine kinase results in intracellular signaling and activation of genes involved in cell growth. Overexpress
Publikováno v:
Oncology. 61:73-82
Measurement of molecular markers predictive of response to therapy should enable more selective and effective utilization of anticancer agents. The predictive value of HER2 remains a complex and inconclusive subject. In metastatic breast cancer, HER2
Autor:
Martine J. Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Richard Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun-Shen Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas M. Suter, Josef Rüschoff, Tamás Sütő, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, M. Stella Dolci, Richard D. Gelber
Publikováno v:
The New England journal of medicine. 353(16)
background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of che
Autor:
M.R. Mattiaci, M. Nooij, Luc Dirix, Tanja Cufer, Caroline Lohrisch, Laura Biganzoli, Gul Atalay, Robert Paridaens, David Cameron, J.P. Lobelle, Martine Piccart, Louk V.A.M. Beex
Publikováno v:
Annals of Oncology, 15, 2, pp. 211-7
Annals of Oncology, 15, 211-7
Annals of Oncology, 15, 211-7
Background: The impact of aromatase inhibitors (AIs) on non-cancer-related outcomes, which are known to be affected by oestrogens, has become increasingly important in postmenopausal women with hormone-dependent breast cancer. So far, data related to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3eb4e2c6b160eff04d82b754589b1ac
https://hdl.handle.net/2066/57464
https://hdl.handle.net/2066/57464
Autor:
David Cameron, Luc Dirix, M. Nooij, A. Hamilton, J.P. Lobelle, Robert Paridaens, Luc Duchateau, Laura Biganzoli, Caroline Lohrisch, Louk V.A.M. Beex, Tanja Cufer, Martine Piccart
Publikováno v:
Annals of Oncology, 14, 1391-8
Annals of Oncology, 14, 9, pp. 1391-8
Annals of Oncology, 14, 9, pp. 1391-8
Item does not contain fulltext BACKGROUND: Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c50e71f1b8480211f6288ce337bcc6
http://hdl.handle.net/2066/185095
http://hdl.handle.net/2066/185095
Autor:
Alan Hilary Calvert, P. Fargeot, Teresa Gamucci, R. Epelbaum, Peter F. Bruning, Laura Biganzoli, Caroline Lohrisch, Luc Duchateau, Robert E. Coleman, Tanja Cufer, Martine Piccart, Chris Twelves
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(14)
PURPOSE: To compare the efficacy and tolerability of the combination of doxorubicin and paclitaxel (AT) with a standard doxorubicin and cyclophosphamide (AC) regimen as first-line chemotherapy for metastatic breast cancer. PATIENTS AND METHODS: Eligi
Autor:
Caroline Lohrisch, Laura Biganzoli, V. Batter, M. Nooij, Louk V.A.M. Beex, Martine Piccart, Tanja Cufer, A. Hamilton, Ahmad Awada
Publikováno v:
European Journal of Cancer, 38, 773-8
European Journal of Cancer, 38, 6, pp. 773-8
European Journal of Cancer, 38, 6, pp. 773-8
Item does not contain fulltext The aim of this study was to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and potential activity of combined gemcitabine and continuous infusion 5-fluorouracil (5-FU) in metastatic breast